Journal of Gynecologic Oncology (JGO) – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Journal of Gynecologic Oncology (JGO)

Forme & Santé

Fréquence : 1 épisode/9j. Total Éps: 37

The Journal of Gynecologic Oncology (JGO) is an official publication of the Asian Society of Gynecologic Oncology (ASGO), the Korean Society of Gynecologic Oncology (KSGO), the Japan Society of Gynecologic Oncology (JSGO), and the Society of Gynecologic Oncology of Canada (GOC).

Lire plusRéduire

Site

RSS

Apple

Données mises à jour le 04/07/2026

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

🇫🇷 France - Medicine
12/06/2026
#82
🇫🇷 France - Medicine
24/09/2025
#91
🇫🇷 France - Medicine
23/09/2025
#61
🇨🇦 Canada - Medicine
11/03/2025
#96

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://doi.org/10.3802/jgo.2024.35.e117
2 partages
https://doi.org/10.3802/jgo.2025.36.e35
1 partage
https://doi.org/10.3802/jgo.2025.36.e15
1 partage

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 32%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

JGO Weekly Summary (July 6, 2025)

dimanche 6 juillet 2025 • Durée 04:13

This episode summarizes a cross-sectional study from Central China on HPV genotype distribution and infection risk factors. Ye Chen and colleagues found that HPV52, 16, and 58 were most common, with infection peaks in young and older women. High-risk factors included diabetes, anxiety, low work intensity, and multiple sexual partners. Condom use and HPV vaccination were protective. The study advocates for integrative prevention strategies including psychosocial and metabolic health management.

Lire plusRéduire

JGO Weekly Summary (May 11, 2025)

dimanche 11 mai 2025 • Durée 04:54

In this episode of the JGO Podcast, we explore a recent study from Peking Union Medical College Hospital examining the role of adjuvant surgery in patients with high-risk chemorefractory or relapsed gestational choriocarcinoma who achieve complete remission following anti-PD-1 therapy. The retrospective analysis of 43 patients reveals no significant difference in survival outcomes between those who underwent surgery and those who did not, raising important questions about the necessity of surgical intervention in this setting. We discuss the implications of these findings in light of current treatment guidelines and emerging data on immunotherapy in gestational trophoblastic neoplasia.

Lire plusRéduire

JGO Weekly Summary (April 29, 2025)

jeudi 1 mai 2025 • Durée 05:54

This episode features an in-depth discussion of the Asian cohort analysis from the AtTEnd/ENGOT-EN7 phase III trial, which evaluated atezolizumab in combination with carboplatin and paclitaxel for advanced or recurrent endometrial carcinoma. While atezolizumab improved progression-free survival in mismatch repair-deficient tumors across both Asian and non-Asian populations, it showed no benefit—and potential harm—in mismatch repair-proficient Asian patients. The analysis also revealed a higher incidence of severe adverse events among Asians receiving atezolizumab. These findings highlight the importance of considering ethnic differences in treatment response and toxicity in future clinical trials.

Lire plusRéduire

JGO Weekly Summary (April 22, 2025)

mardi 22 avril 2025 • Durée 04:39

In this episode, we review findings from the Japan subset of the DUO-E phase III trial, led by Shin Nishio and colleagues, which evaluated durvalumab with or without olaparib following chemotherapy in patients with newly diagnosed advanced or recurrent endometrial cancer. The study demonstrated a progression-free survival benefit in Japanese patients consistent with the global population, with a median of 15.1 months in the durvalumab plus olaparib arm compared to 9.5 months in the control arm. Safety outcomes were manageable and aligned with known profiles of the treatments. These results support durvalumab-based regimens as promising first-line options for Japanese patients.

Lire plusRéduire

JGO Weekly Summary (April 10, 2025)

jeudi 10 avril 2025 • Durée 05:50

In this episode, we discuss the final analysis of the KEYNOTE-826 subgroup study led by Dr. Yong-Man Kim, evaluating pembrolizumab plus chemotherapy with or without bevacizumab in East Asian patients with persistent, recurrent, or metastatic cervical cancer. The study demonstrated substantial improvements in progression-free and overall survival compared to placebo, with median progression-free survival reaching 18.0 months versus 10.4 months in the overall population, and 29.3 versus 10.9 months in patients with PD-L1 expression. Safety was consistent with the known profile of pembrolizumab. These findings support its use as a standard of care in this population.

Lire plusRéduire

JGO Weekly Summary (March 25, 2025)

mercredi 26 mars 2025 • Durée 05:33

In this episode of the Journal of Gynecologic Oncology podcast, we review a recent meta-analysis by Tianyu Zhang and colleagues titled "Role of Adjuvant Chemotherapy in Stage IC Ovarian Granulosa Cell Tumors." The study analyzed data from 12 retrospective studies involving 695 patients to evaluate whether postoperative adjuvant chemotherapy offers any benefit over observation alone. The findings revealed no significant differences in recurrence, mortality, or five-year survival outcomes between the two groups, including across subtypes and chemotherapy regimens. These results suggest limited therapeutic value of adjuvant chemotherapy in stage IC granulosa cell tumors and underscore the need for individualized treatment approaches.

Role of adjuvant chemotherapy in stage IC ovarian granulosa cell tumors: a systematic review and meta-analysis

Lire plusRéduire

JGO Weekly Summary (March 18, 2025)

mercredi 19 mars 2025 • Durée 04:39

In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Baldwin and colleagues titled Evaluation of the Role of Liver Metastasectomy in the Treatment of Stage IV Endometrial Cancer. Using data from the National Cancer Database, the researchers analyzed outcomes in 999 patients with metastatic endometrial cancer confined to the liver. The study found that patients who underwent both chemotherapy and surgical removal of liver metastases had improved survival compared to those who received chemotherapy alone, with a median survival of 20.1 months versus 14.6 months. While the findings suggest a potential benefit of metastasectomy, adjusted analysis did not reach statistical significance, highlighting the need for further prospective studies. Tune in to learn more about the evolving role of surgery in metastatic endometrial cancer treatment.

Evaluation of the role of liver metastasectomy in the treatment of stage IV endometrial cancer

Lire plusRéduire

JGO Weekly Summary (March 11, 2025)

mardi 11 mars 2025 • Durée 05:09

This episode explores a recent study on the increased risk of cardiovascular disease among adolescent and young adult survivors of cervical cancer. Using data from the Korean National Health Insurance Service, researchers found that these survivors face a 47% higher risk of cardiovascular disease compared to non-cancer controls, with those receiving chemoradiotherapy at particularly high risk for heart failure, ischemic heart disease, and venous thromboembolism. The findings highlight the need for long-term cardiovascular monitoring and preventive care in this population. Tune in to learn more about the implications for survivorship care.

Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer

Lire plusRéduire

JGO Weekly Summary (March 4, 2025)

mercredi 5 mars 2025 • Durée 05:35

This episode discusses a multi-institutional study evaluating the impact of bevacizumab in frontline chemotherapy for advanced ovarian clear cell carcinoma. Researchers analyzed data from 178 patients treated between 2008 and 2018 and found that adding bevacizumab significantly improved progression-free and overall survival. Patients who received bevacizumab had a median progression-free survival of 29.7 months compared to 10.5 months in those who did not. Median overall survival was 51.4 months versus 27.4 months. These findings suggest that bevacizumab may be an effective addition to first-line treatment for this rare and chemoresistant ovarian cancer. Tune in to learn more about the study and its clinical implications.

Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma: A multicenter retrospective analysis

Lire plusRéduire

JGO Weekly Summary (February 25, 2025)

samedi 1 mars 2025 • Durée 05:41

In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Kanno and colleagues examining the impact of cytoreductive surgery on outcomes in high tumor burden ovarian cancer following the introduction of poly ADP-ribose polymerase inhibitors. This retrospective analysis of 434 patients found that, while complete cytoreduction remains essential, the use of poly ADP-ribose polymerase inhibitors may improve progression-free survival for patients with extensive tumor burden. However, higher surgical complexity was associated with increased complication rates. These findings highlight the evolving role of maintenance therapy and the importance of optimizing surgical approaches to enhance patient outcomes. Tune in to learn more about the implications for clinical practice in the poly ADP-ribose polymerase inhibitor era.

The Impact of Cytoreductive Surgery on outcomes in High Tumor Burden Ovarian Cancer after induction of PARP inhibitors

Lire plusRéduire

Podcasts et contenus similaires

Autres podcasts ou contenus associés partageant des thèmes ou audiences similaires.

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à Journal of Gynecologic Oncology (JGO). Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !

Il n'y a pas de contenu associé à ce podcast.

À propos Méthodologie Contact Me soutenir Politique de confidentialité Mentions légales

Journal of Gynecologic Oncology (JGO) – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

DOI Foundation26

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Apple Podcasts

Spotify

Podcasts Similaires Basées sur le Contenu

DOI Foundation26